Eliem Therapeutics, Inc.
ELYM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.21 | 0.08 | 0.43 | -0.02 |
| FCF Yield | -5.63% | -28.27% | -38.70% | -13.14% |
| EV / EBITDA | -2.31 | 1.46 | 36.02 | -6.41 |
| Quality | ||||
| ROIC | -38.61% | -19.82% | -34.85% | -21.33% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.14 | 0.59 | 0.83 | 0.76 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 24.45% | 44.88% | -3.60% | -155.87% |
| Safety | ||||
| Net Debt / EBITDA | 1.06 | 6.79 | -29.05 | 1.32 |
| Interest Coverage | 0.00 | 0.00 | -28.33 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |